Genmab - ADR Forecast, price target & analysts
Genmab - ADR Target price 2026 - Analyst rating & recommendation
Genmab - ADR Classifications & Recommendation
Genmab - ADR Price Target
| Target Price | $5.86 |
| Price | $35.57 |
| Deviation |
83.54%
register free of charge
|
| Number of Estimates | 20 |
|
20 Analysts have issued a price target Genmab - ADR 2027 .
The average Genmab - ADR target price is $5.86.
This is
83.54%
register free of charge
$7.36
79.31%
register free of charge
$3.38
90.49%
register free of charge
|
|
| A rating was issued by 27 analysts: 22 Analysts recommend Genmab - ADR to buy, 3 to hold and 2 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Genmab - ADR stock has an average upside potential 2027 of
83.54%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 565.78 | 691.56 |
| 19.15% | 22.23% | |
| EBITDA Margin | 35.54% | 31.69% |
| 3.51% | 10.82% | |
| Net Margin | 25.89% | 16.21% |
| 28.96% | 37.38% |
23 Analysts have issued a sales forecast Genmab - ADR 2026 . The average Genmab - ADR sales estimate is
This results in the following potential growth metrics:
18 Analysts have issued an Genmab - ADR EBITDA forecast 2026. The average Genmab - ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
22 Genmab - ADR Analysts have issued a net profit forecast 2026. The average Genmab - ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 2.34 | 1.82 |
| 12.69% | 22.22% | |
| P/E | 19.39 | |
| EV/Sales | 30.76 |
22 Analysts have issued a Genmab - ADR forecast for earnings per share. The average Genmab - ADR EPS is
This results in the following potential growth metrics and future valuations:
Current Genmab - ADR Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| ROTHSCHILD & CO REDBURN |
Locked
➜
Locked
|
Locked | Sep 23 2026 |
| JYSKE BANK |
Locked
➜
Locked
|
Locked | Sep 23 2026 |
| H.C. WAINWRIGHT & CO., LLC |
Locked
➜
Locked
|
Locked | Sep 14 2026 |
| BNP PARIBAS |
Locked
➜
Locked
|
Locked | Aug 31 2026 |
| DNB CARNEGIE |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| TD COWEN |
Locked
➜
Locked
|
Locked | Aug 06 2026 |
| TRUIST SECURITIES |
Locked
➜
Locked
|
Locked | Aug 06 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
ROTHSCHILD & CO REDBURN:
Locked
➜
Locked
|
Sep 23 2026 |
|
Locked
JYSKE BANK:
Locked
➜
Locked
|
Sep 23 2026 |
|
Locked
H.C. WAINWRIGHT & CO., LLC:
Locked
➜
Locked
|
Sep 14 2026 |
|
Locked
BNP PARIBAS:
Locked
➜
Locked
|
Aug 31 2026 |
|
Locked
DNB CARNEGIE:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
TD COWEN:
Locked
➜
Locked
|
Aug 06 2026 |
|
Locked
TRUIST SECURITIES:
Locked
➜
Locked
|
Aug 06 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
